Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Atomoxetine hydrochloride

Atomoxetine hydrochloride

pharmaceutical raw materials
Atomoxetine hydrochloride structure

Atomoxetine hydrochloride 

structure
  • CAS No:

    82248-59-7

  • Formula:

    C17H21NO.ClH

  • Chemical Name:

    Atomoxetine hydrochloride

  • Synonyms:

    Benzenepropanamine,N-methyl-γ-(2-methylphenoxy)-,hydrochloride (1:1),(γR)-;Benzenepropanamine,N-methyl-γ-(2-methylphenoxy)-,hydrochloride,(R)-;Benzenepropanamine,N-methyl-γ-(2-methylphenoxy)-,hydrochloride,(γR)-;LY 139603;Tomoxetine hydrochloride;(R)-(-)-Tomoxetine hydrochloride;(R)-Tomoxetine hydrochloride;Atomoxetine hydrochloride;(R)-(-)-N-Methyl-3-[(2-methylphenyl)oxy]-3-phenyl-1-aminopropane hydrochloride;Strattera;(R)-N-Methyl-3-(2-methylphenoxy)-3-phenylpropylamine hydrochloride;Atemoxetine hydrochloride;(R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine hydrochloride

  • Categories:

    Biochemical Engineering  >  Inhibitors

Description

Atomoxetine Hcl(LY 139603; Tomoxetine Hcl) is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively). IC50 value: 5 nM (Ki for human NET)Target: NETAtomoxetine displays minimal affinity for a range of other neurotransmitter receptors and transporters (Ki > 1 μM). Atomoxetine is antidepressant and a commonly used non-stimulant treatment for Attention deficit hyperactivity disor


Atomoxetine hydrochloride is the hydrochloride salt of atomoxetine. It has a role as an antidepressant and an adrenergic uptake inhibitor. It contains an atomoxetine.|Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder. Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury.|Atomoxetine Hydrochloride is the hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels.|A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Atomoxetine hydrochloride Basic Attributes

291.82

291.138977

200-659-6

57WVB6I2W0

DTXSID2044266

C47405

2922299090

Characteristics

21.3

4.91750

solid

160-161 °C

389°C at 760 mmHg

9℃

In water, 54.64 mg/L at 25 deg C (est)

2-8°C

1.31X10-5 mm Hg at 25 deg C (est)

D25 -38.01°; 36525 -177.26° (c = 1 in methanol); D23 -41.37° (c = 1.02 in methanol); D25 -40.3° (c = 0.94 in ethanol)

162.4 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Safety Information

UN1230 - class 3 - PG 2 - Methanol, solution

3

11-23/24/25-39/23/24/25

22-24/25-45-36/37-16-7

F,T

P210-P260-P280-P301 + P310-P311

H225-H301 + H311 + H331-H370

|Danger|H301 (66.67%): Toxic if swallowed [Danger Acute toxicity, oral]|P201, P202, P260, P261, P264, P270, P271, P273, P280, P281, P284, P301+P310, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P311, P312, P314, P320, P321, P322, P330, P337+P313, P361, P363, P391, P403+P233, P405, and P501|Aggregated GHS information provided by 9 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Atomoxetine has been linked to serum aminotransferase elevations in a small proportion of patients (~0.5%). More importantly, there have been several reports of clinically apparent acute liver injury due to atomoxetine. The onset of injury was within 3 to 12 weeks of starting the medication. The typical pattern of serum enzyme elevations was hepatocellular with marked increases in serum aminotransferase levels (often >20 times upper limit of normal) and clinical features that resembled acute viral hepatitis. Most cases have been self-limited, but instances of acute liver failure sometimes requiring emergency liver transplantation have been reported. Immunoallergic features were not found, but several patients with acute injury had antinuclear antibody and at least one patient had other features that resembled autoimmune hepatitis (with typical liver histology and high levels of immunoglobulins in serum).

Drug Information

Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder. Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury.

Central Nervous System Stimulants

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)

139603, LY

Atomoxetine hydrochloride Use and Manufacturing

Methods of Manufacturing

(R)-N-methyl-3-(2-methylphenoxy)-benzenepropanamine hydrochloride:; A 3 -necked 100 ml glass reactor was flushed for 15 min with N(R)-N-methyl-3-(2-methylphenoxy)-benzenepropanamine hydrochloride:; A 3 -necked 100 ml glass reactor was flushed for 15 min with N(R)-N-methyl-3-(2-methylphenoxy)-benzenepropanamine hydrochloride:; A 3 -necked 100 ml glass reactor was flushed for 15 min with NUnder stirring and maintaining temperature between 22° C. and 25° C. by means of water bath cooling, 10.07 g (0.09945 mol) of aqueous hydrogen chloride (36percent) were dropped on 177 g (0.08648 mol) of atomoxetine base solution (n-butyl acetate). The hydrochloride then crystallized. The obtained suspension was stirred at about 25° C. for one hour. The solid was collected by filtration and washed twice with 30 ml of n-butyl acetate each time. The solid collected was dried for 18 hours at 70° C. under vacuum. Tomoxetine hydrochloride content: >99percent by HPLC assay. Weight: 25.18 g (0.08629 mol). Yield: 99.8percent. Atomoxetine hydrochloride enantiomeric ratio: R/S>99/1 (by chiral HPLC)45 g (0.110 mol) of (R)-(-)-tomoxetine (S)-(+)-mandelate were mixed under stirring with 225 ml of toluene and 225 ml of water. Keeping the temperature at about 40° C. by means of gentle heating, 21 g (about 0.16 mol) of 30percent aqueous sodium hydroxide were added. The phases were then separated. The organic phase was washed with 100 ml of 1percent aqueous sodium hydroxide, then filtered on paper and concentrated in vacuum to give 29.67 g of an oil containing 26.8 g of tomoxetine (by HPLC assay). 23.5 g of the oil were dissolved in 211 ml of ethyl acetate under stirring then, keeping temperature between 12° C. and 18° C. by means of water-ice bath cooling; gaseous hydrogen chloride was bubbled into the solution until acid reaction of litmus paper. The hydrochloride then crystallized. The obtained suspension was stirred at about 15° C. for one hour, then the solid was collected by filtration, washed with ethyl acetate and dried in vacuo. Tomoxetine hydrochloride content: >99percent by HPLC assay. Weight: 24.3 g (0.0832 mol). Yield: 95percent.

Uses

A Norepinephrine reuptake inhibitor

Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:291.8
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:2
Rotatable Bond Count:6
Exact Mass:291.1389920
Monoisotopic Mass:291.1389920
Topological Polar Surface Area:21.3
Heavy Atom Count:20
Complexity:237
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

No specific description provided

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • ALIVUS LIFE SCIENCES LTD

    United States United States
    Active
  • MATRIX PHARMACORP PRIVATE LTD

    United States United States
    Active
  • HETERO LABS LTD

    United States United States
    Active

Recommended Suppliers of Atomoxetine hydrochloride

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.